Published in AIDS Weekly, September 26th, 2005
"We compared the effectiveness of a biweekly regimen of 150 mg nandrolone with placebo in HIV-infected men with mild to moderate weight loss and contrasted its effects against a Food and Drug Administration (FDA)-approved regimen of recombinant human (rh)GH. In this placebo-controlled, randomized, 12-week trial, placebo and nandrolone (150 mg i.m. biweekly) were administered...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.